JP2017519491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519491A5 JP2017519491A5 JP2016565693A JP2016565693A JP2017519491A5 JP 2017519491 A5 JP2017519491 A5 JP 2017519491A5 JP 2016565693 A JP2016565693 A JP 2016565693A JP 2016565693 A JP2016565693 A JP 2016565693A JP 2017519491 A5 JP2017519491 A5 JP 2017519491A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- terminal
- epitope
- mhc
- multimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 288
- 229920001184 polypeptide Polymers 0.000 claims description 286
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 286
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 65
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 65
- 210000004899 c-terminal region Anatomy 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 230000002519 immonomodulatory effect Effects 0.000 claims description 22
- 230000004957 immunoregulator effect Effects 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000043129 MHC class I family Human genes 0.000 claims description 7
- 108091054437 MHC class I family Proteins 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 5
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 3
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108091054438 MHC class II family Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013715P | 2014-06-18 | 2014-06-18 | |
| US62/013,715 | 2014-06-18 | ||
| PCT/US2015/035777 WO2015195531A2 (en) | 2014-06-18 | 2015-06-15 | Syntac polypeptides and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192453A Division JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Division JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519491A JP2017519491A (ja) | 2017-07-20 |
| JP2017519491A5 true JP2017519491A5 (OSRAM) | 2018-07-26 |
| JP6652932B2 JP6652932B2 (ja) | 2020-02-26 |
Family
ID=54936224
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565693A Active JP6652932B2 (ja) | 2014-06-18 | 2015-06-15 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2019192453A Active JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Active JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2021202405A Active JP7331075B2 (ja) | 2014-06-18 | 2021-12-14 | ｓｙｎＴａｃポリペプチド及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192453A Active JP6652680B2 (ja) | 2014-06-18 | 2019-10-23 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2020009921A Active JP6995151B2 (ja) | 2014-06-18 | 2020-01-24 | ｓｙｎＴａｃポリペプチド及びその使用 |
| JP2021202405A Active JP7331075B2 (ja) | 2014-06-18 | 2021-12-14 | ｓｙｎＴａｃポリペプチド及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20170058015A1 (OSRAM) |
| EP (3) | EP3157552B1 (OSRAM) |
| JP (4) | JP6652932B2 (OSRAM) |
| KR (1) | KR102252119B1 (OSRAM) |
| CN (3) | CN113248624B (OSRAM) |
| AU (3) | AU2015277460B2 (OSRAM) |
| DK (2) | DK3157552T3 (OSRAM) |
| ES (2) | ES2770330T3 (OSRAM) |
| HU (2) | HUE048076T2 (OSRAM) |
| IL (3) | IL248979B (OSRAM) |
| PL (2) | PL3157552T3 (OSRAM) |
| PT (2) | PT3480213T (OSRAM) |
| SG (2) | SG10202006338UA (OSRAM) |
| TW (3) | TWI722576B (OSRAM) |
| WO (1) | WO2015195531A2 (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013557B1 (pt) | 2012-12-11 | 2021-12-14 | Albert Einstein College Of Medicine | Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante |
| WO2017151818A2 (en) * | 2016-03-02 | 2017-09-08 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US20190046648A1 (en) * | 2016-03-03 | 2019-02-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN109689096A (zh) * | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| KR20190019068A (ko) * | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| US11725041B2 (en) * | 2016-08-11 | 2023-08-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| PT3558339T (pt) | 2016-12-22 | 2024-03-15 | Cue Biopharma Inc | Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CA3054955A1 (en) * | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| US11407806B2 (en) | 2017-04-06 | 2022-08-09 | Albert Einstein College Of Medicine | Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells |
| WO2018227286A1 (en) * | 2017-06-12 | 2018-12-20 | Sinai Health System | Allograft tolerance without the need for systemic immune suppression |
| CN107266581B (zh) * | 2017-06-13 | 2021-07-09 | 四川大学 | 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用 |
| MX2020001489A (es) * | 2017-08-10 | 2020-03-20 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. |
| WO2019051126A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF |
| CA3074839A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| IL272085B2 (en) * | 2017-09-07 | 2023-03-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| AU2018328283A1 (en) * | 2017-09-07 | 2020-02-20 | Cue Biopharma, Inc. | Antigen-presenting polypeptides and methods of use thereof |
| KR20190065234A (ko) * | 2017-11-30 | 2019-06-11 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
| SMT202500038T1 (it) | 2018-03-24 | 2025-03-12 | Regeneron Pharma | Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo |
| WO2020056152A1 (en) * | 2018-09-12 | 2020-03-19 | Chang Liu | Single chain constructs |
| WO2020118447A1 (en) * | 2018-12-13 | 2020-06-18 | Sinai Health System | Immunomodulatory cells and uses thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2020132138A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2020132368A1 (en) * | 2018-12-19 | 2020-06-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
| EP3935080A4 (en) * | 2019-03-06 | 2023-04-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| JP7691927B2 (ja) * | 2019-03-06 | 2025-06-12 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 |
| MX2021014476A (es) * | 2019-05-29 | 2022-02-11 | Cue Biopharma Inc | Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos. |
| WO2020257191A1 (en) * | 2019-06-19 | 2020-12-24 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| KR20220066075A (ko) * | 2019-09-20 | 2022-05-23 | 큐 바이오파마, 인크. | T-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| WO2021081239A1 (en) * | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | T-cell modulatory chimeric molecules and methods of use thereof |
| WO2021127495A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021168122A1 (en) * | 2020-02-18 | 2021-08-26 | Institute For Systems Biology | Single chain trimer mhc class ii nucleic acids and proteins and methods of use |
| US20230212259A1 (en) * | 2020-02-21 | 2023-07-06 | 3T Biosciences, Inc. | Yeast display libraries, associated compositions, and associate methods of use |
| US20230126784A1 (en) * | 2020-03-06 | 2023-04-27 | Albert Einstein College Of Medicine | A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP4149953A4 (en) * | 2020-05-12 | 2024-06-26 | Lg Chem, Ltd. | MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2022056015A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof |
| CN112779224A (zh) * | 2021-01-27 | 2021-05-11 | 河南省华隆生物技术有限公司 | 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用 |
| CN112725284A (zh) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | 一种nk滋养层细胞及其应用 |
| CN112725273A (zh) * | 2021-01-27 | 2021-04-30 | 河南省华隆生物技术有限公司 | 一种nk细胞及其制备方法和应用 |
| CN112852744A (zh) * | 2021-01-27 | 2021-05-28 | 河南省华隆生物技术有限公司 | 一种nk滋养层细胞及其制备方法和应用 |
| CA3209361A1 (en) * | 2021-03-19 | 2022-09-22 | Ronald D. Seidel Iii | T-cell modulatory polypeptides and methods of use thereof |
| CA3215077A1 (en) * | 2021-04-07 | 2022-10-13 | Thomas J. Malia | Peptide-mhc-immunoglobulin multimers and methods of use thereof |
| EP4334453A4 (en) * | 2021-05-07 | 2025-09-03 | Inst Systems Biology | SINGLE-CHAIN TRIMER MHC CLASS I NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE THEREOF |
| JP2024534787A (ja) | 2021-08-16 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ２７受容体アゴニスト及びその使用方法 |
| EP4387644A4 (en) * | 2021-08-20 | 2025-10-08 | 3T Biosciences Inc | PEPTIDE-HLA-B*35 LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE |
| EP4460515A1 (en) * | 2022-01-03 | 2024-11-13 | Aarhus Universitet | Proteinaceous compound for generating specific cytotoxic t-cell effect |
| WO2023205728A2 (en) * | 2022-04-21 | 2023-10-26 | Institute For Systems Biology | Soluble single-chain dimers from cleavable single chain trimers |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| JP2025519477A (ja) | 2022-06-07 | 2025-06-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性を調節するための多重特異性分子及びその使用 |
| WO2024059740A1 (en) * | 2022-09-14 | 2024-03-21 | Synthego Corporation | Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof |
| KR20250160369A (ko) | 2023-01-27 | 2025-11-12 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 랩도바이러스 당단백질 및 이의 용도 |
| US20240287186A1 (en) | 2023-02-28 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | T cell activators and methods of use thereof |
| WO2025081106A2 (en) * | 2023-10-12 | 2025-04-17 | Vanderbilt University | Nanobody vaccine compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| US20050003431A1 (en) * | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| WO2002072631A2 (en) * | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Mhc molecule constructs and their usesfor diagnosis and therapy |
| DE102004014983A1 (de) * | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| US8518697B2 (en) * | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| EP2361930A3 (en) * | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| EA020843B1 (ru) * | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| EP2925780B1 (en) | 2012-11-30 | 2017-10-18 | Roche Glycart AG | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| CA3074839A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| EP3737689A4 (en) * | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE |
-
2015
- 2015-06-15 US US15/306,678 patent/US20170058015A1/en not_active Abandoned
- 2015-06-15 KR KR1020167034341A patent/KR102252119B1/ko active Active
- 2015-06-15 PT PT182128017T patent/PT3480213T/pt unknown
- 2015-06-15 PL PL15809277T patent/PL3157552T3/pl unknown
- 2015-06-15 HU HUE18212801A patent/HUE048076T2/hu unknown
- 2015-06-15 DK DK15809277.5T patent/DK3157552T3/da active
- 2015-06-15 CN CN202110210461.1A patent/CN113248624B/zh active Active
- 2015-06-15 PT PT158092775T patent/PT3157552T/pt unknown
- 2015-06-15 DK DK18212801.7T patent/DK3480213T3/da active
- 2015-06-15 SG SG10202006338UA patent/SG10202006338UA/en unknown
- 2015-06-15 CN CN201580027510.0A patent/CN106456733B/zh active Active
- 2015-06-15 CN CN202110210453.7A patent/CN113248623A/zh active Pending
- 2015-06-15 AU AU2015277460A patent/AU2015277460B2/en active Active
- 2015-06-15 HU HUE15809277A patent/HUE047255T2/hu unknown
- 2015-06-15 WO PCT/US2015/035777 patent/WO2015195531A2/en not_active Ceased
- 2015-06-15 EP EP15809277.5A patent/EP3157552B1/en active Active
- 2015-06-15 EP EP18212801.7A patent/EP3480213B1/en active Active
- 2015-06-15 JP JP2016565693A patent/JP6652932B2/ja active Active
- 2015-06-15 ES ES18212801T patent/ES2770330T3/es active Active
- 2015-06-15 SG SG11201609876TA patent/SG11201609876TA/en unknown
- 2015-06-15 ES ES15809277T patent/ES2767259T3/es active Active
- 2015-06-15 PL PL18212801T patent/PL3480213T3/pl unknown
- 2015-06-15 EP EP18212805.8A patent/EP3483179B1/en active Active
- 2015-06-17 TW TW108133859A patent/TWI722576B/zh active
- 2015-06-17 TW TW104119612A patent/TWI696633B/zh active
- 2015-06-17 TW TW110108178A patent/TWI795740B/zh active
-
2016
- 2016-11-15 IL IL248979A patent/IL248979B/en active IP Right Grant
-
2018
- 2018-06-06 US US16/001,153 patent/US20180282392A1/en not_active Abandoned
-
2019
- 2019-05-12 IL IL266570A patent/IL266570B/en active IP Right Grant
- 2019-05-16 AU AU2019203442A patent/AU2019203442B2/en active Active
- 2019-10-23 JP JP2019192453A patent/JP6652680B2/ja active Active
-
2020
- 2020-01-13 US US16/740,752 patent/US20200377569A1/en not_active Abandoned
- 2020-01-24 JP JP2020009921A patent/JP6995151B2/ja active Active
- 2020-06-11 IL IL275307A patent/IL275307B/en unknown
- 2020-08-25 US US17/001,847 patent/US20210238254A1/en not_active Abandoned
- 2020-09-09 US US17/015,282 patent/US20210047384A1/en active Pending
-
2021
- 2021-07-01 AU AU2021204594A patent/AU2021204594B2/en active Active
- 2021-12-14 JP JP2021202405A patent/JP7331075B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519491A5 (OSRAM) | ||
| JP2020511949A5 (OSRAM) | ||
| CN110325205B (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2020514375A5 (OSRAM) | ||
| CN111148756B (zh) | T细胞受体 | |
| JP2021500855A5 (OSRAM) | ||
| US20250074960A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN109311945A (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2019522466A5 (OSRAM) | ||
| WO2019051126A4 (en) | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof | |
| JP2016528244A (ja) | Ｔ細胞レセプター | |
| JP2014519830A5 (OSRAM) | ||
| JP2017507917A5 (OSRAM) | ||
| WO2020132368A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| US20240376177A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| US20230045794A1 (en) | Nk cell-directed chimeric proteins | |
| US20210284712A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN115867310A (zh) | 用于治疗癌症的识别kras g12d的抗cd3的可溶性tors和融合物 | |
| CN107207622B (zh) | Hla-b27同二聚体用于癌症治疗的用途 | |
| JP2020521000A5 (OSRAM) | ||
| JPWO2020243315A5 (OSRAM) | ||
| JPWO2021055594A5 (OSRAM) | ||
| JPWO2020257191A5 (OSRAM) | ||
| US20180355012A1 (en) | Soluble heterodimeric t cell receptor, and preparation method and use thereof | |
| US20230218731A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof |